Literature DB >> 24573597

Diverse roles of miR-29 in cancer (review).

Hesong Jiang1, Guang Zhang1, Jun-Hua Wu1, Chun-Ping Jiang2.   

Abstract

microRNAs (miRNAs) are non-coding RNAs which have the capacity to regulate gene expression at the post-transcriptional level, and have emerging as key factors involved in cancer at all stages ranging from initiation to metastasis. In the present review, we summmarize the diverse roles of the microRNA-29 (miR-29) family in cancer. First, we present a concise introduction to the miR-29 family and the expression profile of miR-29 in various cancer types. We next highlight the upstream regulatory pathway of miR-29 and describe the relationship between miR-29 and cancer in detail. As a tumor suppressor, miR-29 restrains cancer progression by promoting tumor cell apoptosis, by suppressing DNA methylation of tumor-suppressor genes, by reducing proliferation of tumors and by increasing chemosensitivity. However, as a tumor promoter, miR-29 mediates epithelial-mesenchymal transition (EMT) and promotes metastasis in breast cancer and colon cancer. Finally, we suggest that miR-29 represents a novel diagnostic and prognostic biomarker or a therapeutic target for cancer. Our review highlights the diverse relationship between miR-29 and cancer (particularly digestive system neoplasms). Further research of miR-29 in cancer is warranted.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24573597     DOI: 10.3892/or.2014.3036

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  85 in total

Review 1.  Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes.

Authors:  Sasagu Kurozumi; Yuri Yamaguchi; Masafumi Kurosumi; Miki Ohira; Hiroshi Matsumoto; Jun Horiguchi
Journal:  J Hum Genet       Date:  2016-07-21       Impact factor: 3.172

2.  Altered microRNA expression patterns during the initiation and promotion stages of neonatal diethylstilbestrol-induced dysplasia/neoplasia in the hamster (Mesocricetus auratus) uterus.

Authors:  Ramesh Padmanabhan; Isabel R Hendry; Jennifer R Knapp; Bin Shuai; William J Hendry
Journal:  Cell Biol Toxicol       Date:  2017-03-06       Impact factor: 6.691

3.  Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).

Authors:  Heng-Jia Liu; Hilaire C Lam; Christian V Baglini; Julie Nijmeh; Alischer A Cottrill; Stephen Y Chan; Elizabeth P Henske
Journal:  Oncogene       Date:  2019-08-16       Impact factor: 9.867

4.  A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF.

Authors:  Kexiang Zhang; Chaoyue Zhang; Li Liu; Jiahui Zhou
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

Review 5.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

6.  microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism.

Authors:  Peng Ru; Deliang Guo
Journal:  RNA Dis       Date:  2017-03-20

7.  IGF1 3'UTR functions as a ceRNA in promoting angiogenesis by sponging miR-29 family in osteosarcoma.

Authors:  Shuming Gao; Cai Cheng; Hanwen Chen; Min Li; Kehun Liu; Guangya Wang
Journal:  J Mol Histol       Date:  2016-01-12       Impact factor: 2.611

8.  miR-29a suppresses growth and metastasis in papillary thyroid carcinoma by targeting AKT3.

Authors:  Rui Li; Jia Liu; Qun Li; Guang Chen; Xiaofang Yu
Journal:  Tumour Biol       Date:  2015-10-19

Review 9.  The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.

Authors:  Keiichi Koshizuka; Toyoyuki Hanazawa; Ichiro Fukumoto; Naoko Kikkawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-08-25       Impact factor: 3.172

10.  miR-29 Regulates Type VII Collagen in Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Michael Vanden Oever; Daniel Muldoon; Wendy Mathews; Ron McElmurry; Jakub Tolar
Journal:  J Invest Dermatol       Date:  2016-06-18       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.